Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction – Novo Nordisk (NYSE:NVO)
The company also said a separate analysis showed most of the weight lost with Wegovy came from body…
Wegovy Pill Debut ‘Fattens’ Novo Nordisk’s Profit Outlook – Novo Nordisk (NYSE:NVO)
The weight loss drug maker reported first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the…
What’s Going On With Greenland Energy Stock Thursday? – Greenland Energy (NASDAQ:GLND)
Greenland Energy Co. (NASDAQ:GLND) shares are up during Thursday’s premarket session. Highlights Arctic Strategy The company said Tuesday…
Greenland Energy Stock Soars 27% After Halliburton Deal – Greenland Energy (NASDAQ:GLND)
Deal Highlights The agreement covers integrated consulting services and logistical management, including planning, coordination, handling and transportation of…
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children – Novo Nordisk (NYSE:NVO)
Trial Results Show Significant Blood Sugar Reduction Novo Nordisk said its phase 3a PIONEER TEENS trial demonstrated a…
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market – GoodRx Holdings (NASDAQ:GDRX), Novo Nordisk
• GoodRx Holdings shares are advancing steadily. What’s driving GDRX shares up? This move comes amid a growing…
Move Over Novo Nordisk – This Small Company Study Flags Edge In Fatty Liver Drug – Hoth Therapeutics (NAS
Hoth Therapeutics Candidate Shows Impact On Fat Production And Metabolism The HT-VA study demonstrated that parenteral GDNF (Glial…
Novo Nordisk Expands AI Push With ChatGPT Parent OpenAI – Novo Nordisk (NYSE:NVO)
AI To Accelerate Drug Discovery The collaboration will leverage advanced AI tools to analyze complex datasets, identify promising…
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan – Novo Nordisk (NYSE:NVO)
Earlier in March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an…
Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars – Hims & Hers Health (NYSE:HIMS)
Novo Nordisk Partners with Hims & Hers Novo Nordisk has decided to sell its weight-loss drug through Hims…
Roche’s Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly – Roche Holding (OTC:RHHBY)
Genentech on Thursday shared topline results from the Phase 2 ZUPREME-1 trial evaluating petrelintide versus placebo in 493…